On this page
POMGNT2
protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)
POMGNT2 is located on the short (p) arm of chromosome 3, at band 3p22.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 3 in the library →Available at Jeen Health
Clinical tests that include this
Overview
POMGNT2 is located on chromosome 3 and encodes a glycosyltransferase enzyme that participates in the post-translational modification of alpha-dystroglycan. Alpha-dystroglycan is a cell-surface receptor that connects the muscle cell cytoskeleton to the extracellular matrix, maintaining structural integrity during muscle contraction. The enzyme catalyses the addition of N-acetylglucosamine to O-linked mannose residues on alpha-dystroglycan, a critical step in building the glycan structures required for the protein's function.
Disruption of this glycosylation pathway can impair the ability of muscle cells to withstand mechanical stress and can affect neuronal migration during brain development. Variants in POMGNT2 are associated with congenital muscular dystrophies, which present with a range of severity from mild limb-girdle weakness to severe brain and eye abnormalities. The gene belongs to a family of glycosyltransferases that collectively establish the functional glycan coat on alpha-dystroglycan.
What the gene does
The POMGNT2 protein functions as a beta-1,4-N-acetylglucosaminyltransferase, transferring N-acetylglucosamine from UDP-GlcNAc to mannose residues on alpha-dystroglycan. This enzymatic reaction occurs in the endoplasmic reticulum and Golgi apparatus during protein maturation. The resulting glycan chains enable alpha-dystroglycan to bind extracellular ligands such as laminin, a major component of the basement membrane surrounding muscle fibres.
Proper glycosylation of alpha-dystroglycan is essential for maintaining the dystroglycan complex, which links the intracellular actin cytoskeleton to the extracellular matrix. This molecular bridge stabilises muscle cell membranes during contraction and relaxation cycles. In the developing brain, the same complex guides the migration of neurons to their correct positions and helps establish the glial limitans, a barrier structure separating brain tissue from surrounding spaces.
The enzyme works sequentially with other glycosyltransferases to build complex carbohydrate structures. Loss of POMGNT2 activity disrupts this assembly line, resulting in hypoglycosylated alpha-dystroglycan that cannot properly anchor cells to their surrounding matrix. This underlies the muscle weakness and central nervous system abnormalities observed in affected individuals.
Video: Genetics 101
Chromosome location
POMGNT2 is located on the short arm of chromosome 3 at position 22.1, designated cytogenetically as 3p22.1. This chromosomal region contains multiple genes involved in diverse cellular functions. The precise exon count and genomic span of POMGNT2 have been characterised through reference genome sequencing, though detailed structural annotations continue to be refined as transcript isoforms are identified.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein. The POMGNT2 enzyme is predicted to contain a catalytic glycosyltransferase domain responsible for transferring sugar moieties, along with transmembrane regions that anchor it within the membranes of the secretory pathway. The three-dimensional structure and specific residues involved in substrate recognition remain areas of active investigation.
Key variants
Pathogenic variants in POMGNT2 typically result in reduced or absent enzyme activity, leading to insufficient glycosylation of alpha-dystroglycan. Both missense variants that disrupt catalytic activity and truncating variants that produce incomplete protein have been reported. The severity of the associated muscular dystrophy phenotype generally correlates with the residual enzymatic function, with complete loss of activity associated with more severe presentations involving brain and eye malformations.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
Variants in POMGNT2 are associated with a spectrum of congenital muscular dystrophy phenotypes characterised by muscle weakness and variable involvement of the brain and eyes. These conditions fall within the dystroglycanopathy spectrum, a group of disorders caused by defective glycosylation of alpha-dystroglycan. Affected individuals may present with limb-girdle muscular dystrophy, which primarily affects the shoulder and pelvic girdle muscles, or more severe forms involving structural brain abnormalities, intellectual disability, and eye malformations such as myopia or retinal dysplasia. The age of onset and progression vary depending on the specific variants and their impact on enzyme function.
No disease links recorded for this gene in our reference set.
UK clinical status
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does the POMGNT2 gene do?
POMGNT2 encodes an enzyme that adds sugar molecules to alpha-dystroglycan, a protein essential for connecting muscle cells to their surrounding support structures. This modification is necessary for muscle stability and proper brain development.
How are conditions related to POMGNT2 inherited?
Conditions associated with POMGNT2 variants typically follow an autosomal recessive inheritance pattern, meaning an individual must inherit a pathogenic variant from both parents to be affected. Carriers with one variant usually do not show symptoms.
What symptoms might be associated with POMGNT2 variants?
Symptoms vary widely but may include muscle weakness, particularly in the limbs and trunk, along with potential brain abnormalities such as developmental delay or structural changes visible on imaging. Some individuals also experience eye problems, while others have milder disease limited to muscle involvement.